Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.
Shandong Xinhua Pharmaceutical Company Limited has announced its unaudited interim results for the first half of 2025, prepared in accordance with China Accounting Standards for Business Enterprises. This announcement, which is available in both Chinese and English, provides stakeholders with insights into the company’s financial performance during the reporting period, potentially impacting its market positioning and stakeholder decisions.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. It focuses on the production and distribution of pharmaceutical products and is listed on both the Hong Kong Stock Exchange and the Shenzhen Stock Exchange.
Average Trading Volume: 8,369,606
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.52B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.